SpectronRx, a radiopharmaceutical developer and manufacturer, entered into a new partnership agreement with ARTBIO, Inc., a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), to produce a novel prostate cancer therapy, AB001.

SpectronRx will use its state-of-the-art facilities in Indiana to serve as a contract developer and manufacturer for the treatment currently undergoing first-in-human trials. The manufacturing processes will start with ARTBIO’s AlphaDirect technology for isolation of Pb212.

Upon validation, SpectronRx will design, develop, and implement the customized manufacturing line and processes required to scale up production to meet clinical supply requirements. 

“We are excited to be working with ARTBIO to bring their targeted alpha radioligand therapy to patients in need,” said SpectronRx co-founder and CEO John Zehner. “As part of their distributed manufacturing network, we will tap into our expertise in handling and producing medical radioisotopes, such as Pb212, along with our infrastructure for radiopharmaceutical contract development and manufacturing to validate the manufacturing process and produce clinical supplies of AB001.”

“We are pleased to be partnering with SpectronRx once again,” said Daniel Rossetto, head and senior vice president, supply chain and external manufacturing of ARTBIO. “Their expertise and capabilities in radiopharmaceutical development and manufacturing make them an ideal partner for us. With SpectronRx as part of our distributed manufacturing network, we are confident that the clinical supply of AB001 will be made available to patients safely and reliably in Indiana and neighboring states. This is an important milestone as we continue to advance our lead program, AB001, and our entire pipeline.”